News 05 Mar 2024 Immunocore turns to Oncobit platform The British biotechnology company Immunocore will in future make use of the platform developed by Oncobit, a medtech firm and spin-off from the U...
Aktuell 05 Mar 2024 Immunocore setzt auf Plattform von Oncobit Die britische Biotech-Firma Immunocore nutzt in Zukunft die Plattform des Medtech-Unternehmens Oncobit, einer Ausgliederung der Universität Züric...
News 21 Mayo 2024 InSphero partners with Genome Biologics The biotech company InSphero has signed an agreement with Genome Biologics to commercialize the 3D Cardiac Organoid Platform. The platform is at ...
News 10 Mayo 2024 BioVersys extends Series C financing round to 44.9 million Swiss francs BioVersys is bolstering its partnership with GSK in order to accelerate the development of alpibectir for the treatment of tuberculosis. GSK is s...
Aktuell 22 Ene 2024 DISCO Pharmaceuticals startet mit 20 Millionen Euro Kapital DISCO Pharmaceuticals ist mit einem Startkapital von 20 Millionen Euro neu auf dem Markt. Sein Team hat als erstes eine Methode entwickelt, die e...
News 26 Mar 2024 Top Stories from Western Switzerland (March 2024) From innovative approaches in cardiac care and sustainable plastics to enhancing spinal cord injury therapies and advancing virtual power plants,...
News 07 Mayo 2024 UZH researching innovative cancer therapy Researchers from the University of Zurich (UZH) are in the process of developing new cancer therapeutics. Known as radiotheranostics, these drugs...
News 31 Oct 2023 Debiopharm invests CHF 30 million in Valais amidst workforce surge Debiopharm Research & Manufacturing has announced an investment of over CHF 30 million in a Martigny lab expansion as staff numbers rise from 150...
Aktuell 21 Mayo 2024 InSphero spannt mit Genome Biologics zusammen Das Biotech-Unternehmen InSphero hat mit Genome Biologics eine Vereinbarung zur Vermarktung der 3D Cardiac Organoid Platform unterzeichnet. Die P...
News 13 Jun 2023 Merck unveils its cutting-edge Biotech Development Center in Corsier-sur-Vevey German pharmaceutical giant Merck has celebrated the inauguration of its state-of-the-art Biotech Development Center in Corsier-sur-Vevey.
Aktuell 22 Mayo 2024 CUTISS erhält von Investoren 25 Millionen Franken CUTISS hat eine erste Serie C-Finanzierung mit 25 Millionen Franken abgeschlossen. Damit kann das Life Science-Unternehmen der regenerativen Medi...
News 04 Abr 2024 Indivi joins forces with Biogen Indivi and Biogen are cooperating on the development of digital biomarkers for Parkinson’s disease. To this end, the US biotech group is licensin...
News 31 Jul 2023 InSphero announces an award for 3D in vitro models InSphero, based in the canton of Zurich, and the Physicians Committee for Responsible Medicine have launched a joint award program. Five academic...
News 19 Dic 2023 Top Stories from Western Switzerland (October-December 2023) From achieving top rankings in global innovation to making significant advancements in healthcare and technology, discover Western Switzerland's ...
Actualités 17 Abr 2024 Addex Therapeutics lance la spin-off Neurosterix à Genève avec un investissement de USD 63 millions La société genevoise Addex Therapeutics s’est associée à Perceptive Advisors pour lancer la spin-off Neurosterix, un nouvel acteur dans le dévelo...
Aktuell 15 Mayo 2024 Allegria Therapeutics nimmt 3,5 Millionen Dollar in Seed-Runde ein Allegria Therapeutics hat eine Seed-Finanzierung von 3,5 Millionen Dollar durch den Gründungsinvestor Forty51 Ventures erhalten. Das Biotech-Star...